Addition of Bortezomib to Chemotherapy in Newly Diagnosed T-Cell Lymphoblastic Lymphoma (T-LL) and T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Posted: 03/15/2022 | By: Matthew Stenger

Question 1 of 5

The Children's Oncology Group phase III AALL1231 clinical trial studied outcomes in children and young adults with T-ALL/T-LL who were randomly assigned to a modified augmented Berlin-Frankfurt-Münster (BFM) chemotherapy regimen with or without bortezomib. What kind of agent is bortezomib?

Choose 1